文献速递淋巴瘤造血干细胞移植与细胞治疗

接受CD19 CAR-T细胞治疗的弥漫大B细胞淋巴瘤患者器官毒性负担高但非复发死亡率低

DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality.
PubMed 文献 · Blood Adv · 2020-01-01

该研究对60例接受CD19 CAR-T细胞治疗的弥漫大B细胞淋巴瘤(DLBCL)患者进行治疗后第一年按器官系统分组的毒性分析,共观察539例次≥2级和289例次≥3级毒性。1年非复发死亡率为1.7%,总生存率为69%,仅≥3级肺毒性与非复发死亡风险升高相关。

要点

  • 常见≥3级毒性为血液学、代谢、感染和神经并发症,1年累积发生率分别为57.7%、54.8%、35.4%和18.3%。
  • 体能状态受损者≥3级代谢并发症风险更高,乳酸脱氢酶升高与≥3级神经和肺毒性风险更高相关。
  • 细胞因子释放综合征与≥3级代谢、肺和神经并发症发生率更高相关。

核心结论

  • CD19 CAR-T细胞治疗后毒性负担高且因器官系统而异,但大多数毒性可控且很少与死亡相关。
  • 研究强调毒性评估的重要性,可作为进一步研究减少症状负担和改善耐受性的基准。

研究设计与样本

  • 对60例接受CD19 CAR-T细胞治疗的DLBCL患者进行详细分析,评估治疗后第一年按器官系统分组的全部毒性及其与结局的关联。

主要发现

  • 共观察到539例次≥2级毒性和289例次≥3级毒性。
  • ≥3级血液学、代谢、感染和神经毒性的1年累积发生率分别为57.7%、54.8%、35.4%和18.3%。
  • 体能状态受损患者≥3级代谢并发症风险更高,乳酸脱氢酶升高与≥3级神经和肺毒性风险更高相关。
  • 细胞因子释放综合征与≥3级代谢、肺和神经并发症发生率更高相关。
  • 1年非复发死亡率为1.7%,总生存率为69%,仅≥3级肺毒性与死亡风险升高相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cytokine release syndrome (CRS) immune effector cell-associated neurotoxicity syndrome are the most notable toxicities of CD19 chimeric antigen receptor (CAR) T-cell therapy. In addition, CAR T-cell-mediated toxicities can involve any organ system, with varied impacts on outcomes, depending on patient factors and involved organs. We performed detailed analysis of organ-specific toxicities and their association with outcomes in 60 patients with diffuse large B-cell lymphoma (DLBCL) treated with CD19 CAR T cells by assessing all toxicities in organ-based groups during the first year posttreatment. We observed 539 grade ≥2 and 289 grade ≥3 toxicities. Common grade ≥3 toxicities included hematological, metabolic, infectious, and neurological complications, with corresponding 1-year cumulative incidence of 57.7%, 54.8%, 35.4%, and 18.3%, respectively. Patients with impaired performance status had a higher risk of grade ≥3 metabolic complications, whereas elevated lactate dehydrogenase was associated with higher risks of grade ≥3 neurological and pulmonary toxicities. CRS was associated with higher incidence of grade ≥3 metabolic, pulmonary, and neurologic complications. The 1-year nonrelapse mortality and overall survival were 1.7% and 69%, respectively. Only grade ≥3 pulmonary toxicities were associated with an increased mortality risk. In summary, toxicity burdens after CD19 CAR T-cell therapy were high and varied by organ systems. Most toxicities were manageable and were rarely associated with mortality. Our study emphasizes the importance of toxicity assessment, which could serve as a benchmark for further research to reduce symptom burdens and improve tolerability in patients treated with CAR T cells.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wudhikarn K, Pennisi M, Garcia-Recio M, et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv. 2020. PMID: 32614964. doi:10.1182/bloodadvances.2020001972

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。